Saturday 17 October 2026
Export SNGX’s income statement to Excel — free account
Soligenix Inc.
SNGX Healthcare Biotechnology
Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.
0.35
0.01
−2.78%
Follow SNGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.67 | 1.67 | 2.15 | 3.08 | |
Current Ratio |
2.77 | 1.81 | 2.39 | 3.18 | |
Net Debt/EBITDA |
4.68 | 2.09 | 2.28 | 4.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 0.83 | 0.95 | 1.16 | |
Capex/Depreciation |
0.00 | 0.00 | (2.00) | (0.67) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.11) | (0.23) | (0.53) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.23) | (0.53) | (0.68) | |
Cash per Share |
0.62 | 0.59 | 1.53 | 2.43 | |
Shareholders Equity per Share |
0.42 | 0.30 | 1.02 | 1.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.42 | 0.30 | 1.02 | 1.75 | |
Free Cash Flow |
(1.71) | (2.36) | (2.75) | (2.93) | |
Working Capital |
6.50 | 2.95 | 5.15 | 7.46 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
6.32 | 2.73 | 4.91 | 7.19 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.03 | 0.71 | 0.89 | 1.05 | |
Average Assets |
8.13 | 7.33 | 9.10 | 10.89 | |
Average Common Equity |
4.24 | 3.35 | 4.71 | 6.77 |
Columns are period end dates